Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.

Key Takeaways Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of pocket.The company also launched new 7.5-mg and 10-mg single-use vials, which cost $499 when refilled every 45 days through Eli Lilly's new "Zepbound Self Pay Journey Program.

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells.